Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept

Autor: Akira Machida, Akio Oishi, Junichiro Ikeda, Junko Kurihara, Ai Yoneda, Eiko Tsuiki, Yuki Hirata, Ryuya Murakami, Takashi Kitaoka
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Life, Vol 14, Iss 4, p 476 (2024)
Druh dokumentu: article
ISSN: 14040476
2075-1729
DOI: 10.3390/life14040476
Popis: We investigated the factors associated with the success of switching to faricimab for type 1 macular neovascularization (MNV) refractory to intravitreal aflibercept (IVA). This retrospective cohort study included patients with type 1 MNV who were switched to faricimab because they were refractory to IVA at two centers. The primary endpoint was a more than two-week extension of the treatment interval after 6 months. In addition, factors related to the success or failure of extension and visual and anatomical outcomes were assessed. The analysis included 43 eyes from 43 patients. Extended dosing intervals of >2 weeks were identified in 14 eyes (32.6%). A short dosing interval before switching, absence of polypoidal lesions, and thin central choroidal thickness before switching were identified as factors involved in successful extension. For patients with refractory type 1 MNV, switching to faricimab is a safe and potential option to extend existing dosing intervals.
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje